No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
LABU Direxion Daily S&P Biotech Bull 3x Shares ETF
- 87.640
- +3.920+4.68%
Trading Apr 26 12:19 ET
87.680High82.000Low
87.680High82.000Low1.52MVolume84.730Open83.720Pre Close130.01MTurnover15.22%Turnover Ratio--P/E (Static)10.00MShares176.76252wk High--P/B876.40MFloat Cap48.23652wk Low0.58Dividend TTM10.00MShs Float4717.402Historical High0.67%Div YieldTTM6.78%Amplitude48.234Historical Low85.429Avg Price1Lot Size
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
BioMarin Pharmaceutical Is Maintained at Hold by Canaccord Genuity
BioMarin Pharmaceutical Is Maintained at Hold by Canaccord Genuity
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q1 2024 Earnings Call Transcript
Express News | Canaccord Genuity Maintains Hold on Biomarin Pharmaceutical, Lowers Price Target to $89
Rendimiento Legendario, Potencia Moderna: Toyota Tacoma 2024 Con I-FORCE MAX
La primera Tacoma con motor híbrido i-FORCE MAX produce hasta 326 HP y 465 lb-pie de torque i-FORCE MAX de serie en las versiones Trailhunter y TRD Pro, y opcional en TRD Sport, TRD Off-Road y Limit
Results: BioMarin Pharmaceutical Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) shareholders are probably feeling a little disappointed, since its shares fell 8.8% to US$82.17 in the week after its latest quarterly results. It look
Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), PTC Therapeutics (PTCT) and Teladoc (TDOC)
Comments
$Direxion Daily S&P Biotech Bull 3x Shares ETF(LABU.US$ The bull rjn here was very good today ! I will look for pull back here
1
Healthcare and Biotech are Absolutely Ripping!
These are the best performing sectors to start the first day of the new year.
This could be due to the fact that biotech and healthcare were nowhere near the top performers last year.
The defensive aspect of these sectors could be adding to their appeal since SPY is starting off 2024 on a bad foot.
If you like these sectors, then I suggest checking out the well-known large cap companies in these sectors as an investment prospect. Here are just a few...
This could be due to the fact that biotech and healthcare were nowhere near the top performers last year.
The defensive aspect of these sectors could be adding to their appeal since SPY is starting off 2024 on a bad foot.
If you like these sectors, then I suggest checking out the well-known large cap companies in these sectors as an investment prospect. Here are just a few...
10
Read more